We have assembled an experienced team of executives with track records of success. Our leadership team is well versed in development, commercial, operational, and corporate functions—each crucial for long-term growth and well-being of a successful pharmaceutical business.
Dr. Hung has served as our Chief Executive Officer and member of the board since April 2017. Previously, he was a cofounder of Medivation, Inc., a biopharmaceutical company, and served as its President and Chief Executive Officer and a member of its board of directors until its acquisition by Pfizer Inc. Before that, Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as Chief Scientific Officer and then as President and Chief Executive Officer. He also served as a consultant to Cytyc Corporation to assist with transitional matters related to its acquisition of ProDuct Health, Inc.
Dr. Hung received an M.D. from the University of California, San Francisco (UCSF) School of Medicine, and an A.B. in biology and organic chemistry from Harvard College. He also completed clinical training in internal medicine, hematology, oncology, and transfusion medicine and then 2 basic science postdoctoral fellowships in brain tumor and cardiovascular research, all at UCSF School of Medicine.
Ms. McCourt has served as our President and Chief Operating Officer since April 2017. She has more than 20 years of wide-ranging experience at some of the world’s most innovative biopharmaceutical companies. She has extensive experience leading commercial functions including medical affairs, business development, finance, human resources, legal, operations, payer-government, and sales and marketing. Before joining Axovant, she was Chief Operating Officer of Medivation, Inc., until its acquisition by Pfizer Inc. Earlier in her career, she held multiple roles at Amgen including Vice President of U.S. Commercial Operations and Vice President and General Manager, where she was responsible for the bone health and primary care business unit. She also served in a number of roles of increasing responsibility during a 12-year career at AstraZeneca including, ultimately, Chief Operating Officer for AstraZeneca U.S.
Ms. McCourt received a B.S. in biology from Lafayette College.
Mr. Altmeyer is Chief Commercial Officer of Axovant Sciences GmbH and joined our company in March 2015. He has 30 years of experience leading successful drug commercialization efforts as a pharmaceutical executive, with a focus on therapies for central nervous system disorders. Previously, he served as Chief Executive Officer and President of Otsuka America Pharmaceutical, Inc., where he led 1,700 employees and grew total revenues from $2.6 billion to over $5 billion. He led the launch of Abilify®, the top-selling CNS drug in history and the number-one selling drug in the United States in 2013. Earlier in his career, Mr. Altmeyer held a number of executive leadership roles at Bristol-Myers Squibb, including Senior Vice President, Global Commercialization, and Senior Vice President, Neuroscience Business Unit.
Mr. Altmeyer received an M.B.A. from Harvard Business School and a B.A. in economics from Middlebury College.
Mr. Mohr has served as our General Counsel since June 2017. He has more than 25 years of experience in legal and compliance matters affecting the pharmaceutical industry. He served in a number of senior roles during a 12-year career at AstraZeneca, including U.S. General Counsel and Deputy General Counsel, North America, and Global Compliance Officer. Prior to that, he held roles of increasing responsibility during a 14-year career at Bristol-Myers Squibb, including Vice President and Senior Counsel, U.S. Medicines. Earlier in his career, he specialized in litigation matters at Weiss Dawid Fross Zelnick & Lehrman, PC (now Fross Zelnick Lehrman & Zissu) and Rivkin Leff Sherman & Radler (now Rivkin Radler LLP).
Mr. Mohr received a J.D. from the University of Virginia School of Law and a B.A. in music from Yale University.
Dr. Friedhoff has served as our Chief Development Officer since May 2015. He has a 30-year record of identifying promising drug candidates and managing all phases of their development, always with an eye toward fulfilling drug approval requirements. He has managed post–FDA-approval activities including marketing-related, safety surveillance, and post-approval studies. Previously, he held positions at Eisai, Squibb, and Andrx Corporation. At Eisai, he led the drug development team for Aricept® (donepezil), the top-selling Alzheimer’s disease drug in history, and the new drug approval team for AcipHex® (rabeprazole) for the treatment of heartburn. He is the author of the book New Drugs and author or coauthor of many peer-reviewed publications in major scientific journals. He also is Chief of Research and Development at Roivant Sciences, Inc.
Dr. Friedhoff received an M.D. from New York University School of Medicine, a Ph.D. in chemistry from Columbia University, and a B.S. in chemistry from New York University. He is a fellow of the American College of Physicians.
Dr. Lombardo has served as our Senior Vice President, Clinical Research, since April 2015. She has 15 years of experience leading clinical development and medical affairs programs across multiple therapeutic areas including neurological and psychiatric disorders. She has successfully managed clinical development, regulatory authority approval, and post-marketing activities. Previously, she was Vice President, Clinical Development and Medical Affairs, at FORUM Pharmaceuticals. Earlier in her career, she led multitherapeutic groups and development teams at Pfizer. She is a trained psychiatrist and previously worked in academic research and clinical practice. Prior to entering the pharmaceutical industry, she was an Assistant Professor of Clinical Research at Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute.
Dr. Lombardo received an M.D. from Yale University, an M.Phil. from the University of Cambridge, and an A.B. in philosophy from Brown University. She completed a research fellowship in molecular biology at Yale University and the University of Cambridge, and completed her internship and residency in psychiatry as well as a four-year post-doctoral fellowship in molecular neuroimaging at Columbia University College of Physicians and Surgeons.
Dr. Weinhoff has served as our Chief Financial Officer since August 2015. He has more than 20 years of experience in healthcare finance and operations, including as a venture capital investor, operating executive, and board member with Audit Committee experience. Previously, he was a partner at CHL Medical Partners, where he focused on investments in start-up and early-stage companies across therapeutics, diagnostics, medical devices and healthcare services. He was the founding Chief Executive Officer of Amicus Therapeutics and subsequently was a member of the Audit Committee of the company’s board of directors. Earlier in his career, he was founding President of VaxInnate and President of Resolvyx. He also held positions in the healthcare groups at J.H. Whitney & Co. and Morgan Stanley & Co.
Dr. Weinhoff received an M.D. from Harvard Medical School, an M.B.A. from Harvard Business School (Baker Scholar), and an A.B. in economics from Harvard College.
Dr. Floyd has served as our Senior Vice President, Regulatory Affairs, since June 2017. He has nearly 20 years of regulatory experience within the pharmaceutical industry. Most recently, he was President of Compliance Services and Chief Scientific Officer at Dohmen Life Science Services, Inc. He also served as Senior Vice President, U.S. Regulatory Affairs, and Clinical Quality Compliance at Lundbeck Inc., Global Vice President of Regulatory Affairs at Hospira, Vice President of Worldwide Regulatory Affairs and Quality Assurance at Cephalon, and Vice President and Global Head of Respiratory, Dermatology, and Tropical Medicines Drug Regulatory Affairs at Novartis. He also held senior leadership roles at Bristol-Myers Squibb, Aventis, and Merck Research Laboratories.
Dr. Floyd received a Ph.D. from Meharry Medical College, Nashville, an M.B.A. from St. Joseph’s University, Philadelphia, an M.S. from Tennessee State University, and a B.S. in biology from the University of Illinois.
Dr. Templeman has served as our Senior Vice President, Pharmaceutical Operations and Quality Assurance, since June 2017. He has more than 25 years of experience across various aspects of pharmaceutical operations. He most recently served as Chief Operations Officer at Graybug Vision and was at Medivation prior to that. He previously held positions of increasing responsibility at Hospira, Inc., Liquidia Technologies, and Johnson & Johnson companies Centocor Biologics and Ortho Clinical Diagnostics.
Dr. Templeman received a Ph.D. from Dartmouth College and a B.S. in biology from Santa Clara University.
Mr. Wadley has served as our Senior Vice President, U.S. Business, since May 2017. He has nearly 25 years of commercial leadership experience across sales, marketing, payer access and commercial operations. Mr. Wadley most recently served as Senior Vice President of Sales at Guardant Health and previously was Vice President, Oncology Sales, Organized Customers, and Payer at Medivation, Inc. He has also held various roles of increasing responsibility at Amgen, Wyeth BioPharma, and Genetics Institute.
Mr. Wadley received a B.S. in purchasing and logistics management from Arizona State University.
Ms. Bari has served as our Vice President, Corporate Communications, since May 2017. She has more than 25 years of U.S. and global communications experience in the healthcare and pharmaceutical industries. Most recently, she was Vice President of Corporate Communications at Medivation, Inc. and, prior to that, Senior Vice President of Corporate Communications at Pharmacyclics. She has also held positions of increasing responsibility at Ikaria, Johnson & Johnson, and Pfizer Inc., in addition to having held senior-level positions at several of the world’s leading global communications firms. She began her career at a New York teaching hospital.
Ms. Bari received an M.A. in liberal studies and a B.A. in journalism from New York University.
Dr. Ramaswamy is our Vice President of Global Medical Affairs and joined the company in March 2015. One of the earliest employees of Axovant, he has served the company in multiple roles including, most recently, Vice President, Medical and Scientific Communications, and was involved in the scientific evaluation of new assets for Axovant.
Dr. Ramaswamy received an M.D. from Brown University and an A.B. in economics from Harvard University.
* Employee and officer of Axovant Sciences, Inc.
** Employee and officer of Axovant Sciences GmbH